Literature DB >> 31448486

Myosteatosis to predict inferior perioperative outcome in patients undergoing orthotopic liver transplantation.

Zoltan Czigany1, Wiebke Kramp1, Jan Bednarsch1, Gregory van der Kroft1, Joerg Boecker1, Pavel Strnad2, Markus Zimmermann3, Ger Koek4, Ulf Peter Neumann1,5, Georg Lurje1.   

Abstract

Muscle wasting and alterations of body composition are linked to clinical outcomes in numerous medical conditions. The role of myosteatosis in posttransplant outcomes remains to be determined. Here we investigated skeletal muscle mass and myosteatosis as prognostic factors in patients undergoing orthotopic liver transplantation (OLT). The data of 225 consecutive OLT recipients from a prospective database were retrospectively analyzed (May 2010-December 2017). Computed tomography-based skeletal-muscle-index (muscle mass), visceral-fat-area (visceral adiposity), and mean skeletal-muscle-radiation-attenuation (myosteatosis) were calculated using a segmentation tool. Cut-off values of myosteatosis resulted in a good stratification of patients into low- and high-risk groups in terms of morbidity (Clavien-Dindo ≥3b). Patients with myosteatosis had significantly higher complication rates (90-day Comprehensive Complication Index 68 ± 32 vs 44 ± 30, P < .001) and also displayed significantly longer intensive care (18 ± 25 vs 11 ± 21 days, P < .001) and hospital stay (56 ± 55 vs 33 ± 24 days, P < .001). Estimated costs were 44% higher compared to patients without myosteatosis. Multivariable analysis identified myosteatosis as an independent prognostic factor for major morbidity (odds ratio: 2.772, confidence interval: 1.516-5.066, P = .001). Adding myosteatosis to the well-established Balance-of-Risk-(BAR) score resulted in an increased prognostic value compared to the original BAR score. Myosteatosis may be a useful parameter to predict perioperative outcome in patients undergoing OLT, supporting the role of muscle quality (myosteatosis) over quantity (muscle mass) in this setting.
© 2019 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  body composition; clinical decision-making; clinical research/practice; complication; liver transplantation/hepatology; myosteatosis; sarcopenia

Year:  2019        PMID: 31448486     DOI: 10.1111/ajt.15577

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  13 in total

Review 1.  Novel approaches to metabolic assessment and structured exercise to promote recovery in ICU survivors.

Authors:  Jeroen Molinger; Amy M Pastva; John Whittle; Paul E Wischmeyer
Journal:  Curr Opin Crit Care       Date:  2020-08       Impact factor: 3.687

2.  Influence of skeletal muscle mass on graft regeneration after living-donor liver transplantation.

Authors:  Deniz Uluk; Johann Pratschke; Georg Lurje
Journal:  Hepatobiliary Surg Nutr       Date:  2021-08       Impact factor: 7.293

3.  High visceral adipose tissue area is independently associated with early allograft dysfunction in liver transplantation recipients: a propensity score analysis.

Authors:  Guanjie Yuan; Shichao Li; Ping Liang; Gen Chen; Yan Luo; Yaqi Shen; Xuemei Hu; Daoyu Hu; Jiali Li; Zhen Li
Journal:  Insights Imaging       Date:  2022-10-11

4.  Skeletal Muscle Composition Predicts Outcome in Critically Ill Patients.

Authors:  Sven H Loosen; Maximilian Schulze-Hagen; Tobias Püngel; Lukas Bündgens; Theresa Wirtz; Jakob N Kather; Mihael Vucur; Pia Paffenholz; Münevver Demir; Philipp Bruners; Christiane Kuhl; Christian Trautwein; Frank Tacke; Tom Luedde; Alexander Koch; Christoph Roderburg
Journal:  Crit Care Explor       Date:  2020-08-05

5.  A new sarcopenia score prognostic for postoperative complications in hepatic alveolar echinococcosis: a multicenter retrospective study.

Authors:  Tao Wang; Xianwei Yang; Wanxiang Wang; Tingyu Chen; Junjie Kong; Shu Shen; Ying Chen; Gengfu Wei; Dinggang Yu; Cong Wang; Minghao Li; Shaozhen Rui; Biao Luo; Wentao Wang
Journal:  Ann Transl Med       Date:  2020-11

6.  A Sarcopenia-Based Prediction Model for Postoperative Complications of ex vivo Liver Resection and Autotransplantation to Treat End-Stage Hepatic Alveolar Echinococcosis.

Authors:  Ting Sun; Tao Wang; Yiwen Qiu; Shu Shen; Xianwei Yang; Yi Yang; Bin Huang; Wentao Wang
Journal:  Infect Drug Resist       Date:  2021-11-23       Impact factor: 4.003

7.  The Role of Sarcopenia and Myosteatosis in Short- and Long-Term Outcomes Following Curative-Intent Surgery for Hepatocellular Carcinoma in a European Cohort.

Authors:  Franziska Alexandra Meister; Georg Lurje; Suekran Verhoeven; Georg Wiltberger; Lara Heij; Wen-Jia Liu; Decan Jiang; Philipp Bruners; Sven Arke Lang; Tom Florian Ulmer; Ulf Peter Neumann; Jan Bednarsch; Zoltan Czigany
Journal:  Cancers (Basel)       Date:  2022-01-30       Impact factor: 6.639

8.  Myosteatosis as an independent risk factor for mortality after kidney allograft transplantation: a retrospective cohort study.

Authors:  Antoine Morel; Yaniss Ouamri; Florence Canouï-Poitrine; Sébastien Mulé; Cécile Maud Champy; Alexandre Ingels; Vincent Audard; Alain Luciani; Philippe Grimbert; Marie Matignon; Frédéric Pigneur; Thomas Stehlé
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-11-05       Impact factor: 12.910

9.  Various myosteatosis selection criteria and their value in the assessment of short- and long-term outcomes following liver transplantation.

Authors:  Franziska Alexandra Meister; Jan Bednarsch; Iakovos Amygdalos; Joerg Boecker; Pavel Strnad; Philipp Bruners; Sven Arke Lang; Tom Florian Ulmer; Lara Heij; Daniel Antonio Morales Santana; Wen-Jia Liu; Georg Lurje; Ulf Peter Neumann; Zoltan Czigany
Journal:  Sci Rep       Date:  2021-06-28       Impact factor: 4.379

Review 10.  Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies.

Authors:  Annalisa Cespiati; Marica Meroni; Rosa Lombardi; Giovanna Oberti; Paola Dongiovanni; Anna Ludovica Fracanzani
Journal:  Biomedicines       Date:  2022-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.